Skip to content
PortiVixBy VirtuNx
Capabilities

Product depth built for how pharma teams actually decide.

From molecule intelligence and risk scoring to NPV/eNPV, materials readiness, and audit-ready governance - every capability stays connected to the same asset record.

Where PortiVix leads

Five capabilities that generic tools cannot replicate.

01

Molecule Intelligence

A governed asset record from FDA-assisted import through enrichment, phase gates, and snapshots.

02

Risk Intelligence

PTRS, Business, IP, API/Supply, and KSM scoring separated from delivery risk and issues.

03

NPV / eNPV

Risk-adjusted value connected to probability, assumptions, and actuals.

04

Audit-ready governance

Traceability created as work happens - actor identity, change history, checksum, export.

05

Pharma project execution

Milestone -> task -> subtask, dependencies, critical path, risks, and issues.

Molecule intelligence

Build and manage every asset record from one governed source of truth.

Create molecules manually or use the Portfolio Builder to start from public FDA datasets - then enrich each asset with commercial assumptions, phase gates, patent fields, risks, financials, materials, documents, and snapshots.

Portfolio Builder

FDA-assisted drug search and Orange Book-style data workflows to start a molecule record.

  • Raw source payload stored for imported records
  • Manual enrichment after creation
  • Public data gives a starting point; your teams validate and enrich

Molecule profile

A complete asset profile across pharma, patent, and lifecycle fields.

  • Dosage form, route, strength, container, storage, brand
  • Filing category, market, development model
  • Patent/IP: DS, DP, and AoP expiry dates
  • Phase timelines, baselines, snapshots, hold/resume lifecycle, task boards
VX-330 · moleculeon-track
Phase
Ph II · active
PTRS
68%
Patent (DS)
2031
eNPV
$412m
Portfolio governance

Leadership visibility without a briefing-pack dependency.

Live visibility into molecule status, project progress, phase movement, risks, issues, resources, and financial signals across the pipeline.

Portfolio Command Centre

Portfolio Trends

Programme-level PMO Governance Dashboard

Portfolio and project Gantt views

Access rules by user, role, and discovery mode

Named owner accountability

Governed execution

Milestone to activity, with critical path, risks, and issues in one plan.

Structured project plans move pharma teams from informal coordination to accountable execution: Project -> Milestone -> Task -> SubTask, with dependencies, critical path, an interactive Gantt, a project risk register, and an issue tracker.

project · plan & critical pathMilestone → Task → SubTask
Q1Q2Q3Q4
M1 · Ph II readiness
Formulation development
Prototype trials
Analytical method (ADL)
Stability setup
R
M2 · Exhibit batch
Scale-up / exhibit batch
R
Regulatory dossier (ANDA)
I
M3 · Submission
Critical pathTask / subtaskMilestoneRiskIssue

Plan structure

  • Milestones, tasks, subtasks, activities
  • Dependencies: FS, SS, FF, SF with lag days
  • Interactive Gantt and critical path indicators
  • Template lock mechanics for governed plans

Risk, issues & sign-off

  • Project risk register: probability, impact, owner, mitigation, residual risk
  • Issue tracker: blockers, deviations, change requests, escalation
  • Task approvals, pending queue, rejection reasons, sign-off
  • Comments, @mentions, documents, activity feed, audit trail
Risk and issue control

Know where risk sits before it becomes a missed milestone or bad capital decision.

PortiVix separates molecule-level decision risk from project-level delivery risk and active issues - giving leadership and PMO teams a clearer view of what could go wrong and what already has.

PTRS

Probability of technical and regulatory success at phase gates.

Business Risk

Commercial viability, competition intensity, and strategic fit.

IP Risk

Freedom-to-operate, patent vulnerability, and patent cliff exposure.

API / Supply Risk

Supplier concentration, lead time, country risk, and regulatory supply exposure.

KSM Risk

Tenant-defined key success metrics with scoring and commentary.

Project Risk Register

Probability, impact, owner, mitigation, contingency, residual risk, review date, status.

Issue Tracker

Blockers, deviations, change requests, linked tasks, comments, and escalation.

risk profile5 frameworks
PTRS68
Business74
IP52
API / Supply61
KSM80
NPV and eNPV

Connect capital decisions to molecule risk and execution reality.

Each molecule can carry a financial model with NPV and expected NPV - so leaders and finance teams understand value, probability, assumptions, and actuals in the same context as phase gates and risk. Try it: adjust the inputs and watch eNPV move.

molecule · financial modelwhat-if · live
$600m
55%
10%
4yr
$250m
NPV (unrisked)$631m
eNPV (risk-adjusted)$235m
Phase-gate signalHold / re-baseline

Illustrative model. In PortiVix, eNPV connects to real assumptions, actuals, PTRS, and risk on each molecule.

Model inputs

API price, COGS, annual demand, overhead, other costs, investment, discount rate, project duration, probability of success, and start year.

Outputs & actuals

  • NPV and eNPV for risk-adjusted prioritisation
  • Annual cashflow actuals for comparison against the model
  • What-if recalculation on save

Pharma decision flow

01Molecule profilecommercial & patent fields
02Risk scoringPTRS · IP · API · KSM
03NPV / eNPVrisk-adjusted value
04Phase-gate decisiongo / kill evidence
05Audit recordattached as it happens
Materials and supply chain

Bring material readiness into the same view as molecule and project decisions.

For API, formulation, and development teams, material and vendor readiness can decide whether timelines are real.

DQ, SU, EB, and Commercial quantity planning

Material items: type, CAS number, UOM, contribution %

Vendor records: unit price, budget, lead time, country of origin, markets

Materials Dashboard for portfolio-level KPIs

Version history for traceability

20+ reports and AI-assisted intelligence

Reports built around decisions, not around what happens to be available.

Strategic, monitoring, operational, and compliance reports with saved views, scheduled delivery, exports, and AI-assisted portfolio questions that respect user access permissions.

Strategic

Portfolio Command Centre, PMO Governance Dashboard, Portfolio Trends, My Dashboard

Monitoring / Control Tower

Risk Control Tower, Issue Control Tower, Milestone Governance, Resource Utilisation

Operational

Project Summary, Task Completion, Workstream Progress, Milestone Tracking, Project Burndown, Employee Utilisation

Data & Compliance

Risk Registry, Issue Registry, Portfolio Health, Audit & Compliance

AI Assistant

Ask portfolio questions such as at-risk molecules, top eNPV opportunities, and portfolio health summaries. AI access is scoped by RBAC and audited through tools-used tracking - it only uses the data available to the authenticated user.

Governance, audit & compliance

Evidence that exists before you need it.

Approval, phase, change, and audit records stay connected to the work as it happens - supporting regulated electronic-record readiness, including 21 CFR Part 11 readiness workflows, subject to customer validation.

Audit trail flow

01Actioncreate · update · export
02Actoridentity · role · IP
03Timestampsession context
04Before / after statechange captured
05Checksumintegrity verification
06ExportCSV for review

See these capabilities mapped to your workflows.

We do not start with a generic demo. We map your portfolio, molecule, project, approval, reporting, and governance workflows first - then show how PortiVix would work for your organisation.